Stealth BioTherapeutics Corp is a clinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market treatments for illnesses arising from mitochondrial dysfunction. Its primary therapeutic candidate, Elamipretide, is currently progressing through multiple clinical stages: a Phase 3 trial for Barth Syndrome and replisome myopathies; a Phase 2/3 study for Duchenne cardiomyopathy; a Phase 2a investigation for Friedreich's ataxia; and Phase 2 trials for both dry age-related macular degeneration and Leber's hereditary optic neuropathy. The company's developmental pipeline further includes SBT-20, designed to address complications associated with diabetes, various renal and ocular conditions, and several neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's, and ALS. Additionally, SBT-550 is being evaluated for rare neurological indications, while SBT-272, a peptidomimetic, is engineered to target and enhance mitochondrial function amidst oxidative stress. Established in 2006, Stealth BioTherapeutics Corp operates from its base in George Town, Cayman Islands.


Net sales
Gross margin
Net income